Gabapentin
Product Images NDC 68071-2883

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2883). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2883 1)

Prescription drug label for Gabapentin 300mg capsules from NuCare Pharmaceuticals, Inc. The label indicates a package count of 100 capsules. It includes barcodes, NDC 68071-2883-1, and storage instructions to keep the medication at controlled temperatures (68-77°F). Additional manufacturing and lot information appear on the label.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An illustration depicting the formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients. The formula is structured for use in clinical calculations.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin, showing a cyclohexane ring attached to a central carbon bonded to an amino methyl group and a carboxymethyl group.*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting mean pain scores over an 8-week period for placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks from baseline through week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. The Gabapentin group shows a downward trend in pain scores over time, while the placebo group remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks with baseline and subsequent weeks 1 to 7; the y-axis represents mean pain scores from 0 to 10. Two time periods are indicated: a 3-week dose titration period and a 4-week fixed dose period. Scores for both Gabapentin doses decrease over time more than placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar graph titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different doses across two studies. The y-axis shows percentage responder rates from 0% to 100%. Study 1 bars show 12% for placebo and 29% for GBP 3600 mg, while Study 2 bars show 14% placebo, 32% GBP 1800 mg, and 34% GBP 2400 mg. Statistical significance markers indicate p-values less than 0.01 and 0.001 for Gabapentin doses.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart illustrating the percentage difference versus daily dose in mg for Gabapentin across three studies labeled a, b, and c. The x-axis displays daily doses at 600, 900, 1200, and 1800 mg, while the y-axis represents the difference percentage ranging from 2% to 22%. Data points for each study are differentiated by color and markers.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.